A phase II Study of Electroporation Potentiated Immunotherapy in Liver Metastatic Pancreatic Cancer

Project Details

Description

An investigator initiated clinical trial of combined immunotherapy (PD1-inhibitor) and irreversible electroporation in patients with metastatic pancreatic cancer.
The aim is to examine the efficacy and safety of the combined treatment.
Short titleElectroporation Potentiated Immunotherapy in Cancer – 1.st study
AcronymEPIC-1
StatusActive
Effective start/end date01/01/2021 → 31/12/2025

Collaborative partners

  • Odense University Hospital

Keywords

  • pembrolizumab
  • irreversible electroporation
  • efficacy
  • safety
  • cancer
  • pancreatic cancer
  • pancreas
  • immunotherapy
  • ablation

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.
View full fingerprint